🍺❌On 11 December 2024, EASL, represented by Aleksander Krag Shira zelber sagi, and Frank Murray, partnered with WHO/Europe to launch the European Alcohol Health Alliance Symposium in Copenhagen. During the symposium, representatives from 21 pan-European medical societies and health

Excellent review on steatotic liver disease. #MASLD #MASH Aleksander Krag pubmed.ncbi.nlm.nih.gov/39488409/

Impact of under reporting of alcohol consumption in persons with Steatotic Liver Disease? What is the true distribution of MASLD vs MetALD/ALD in the population ? 😳10-57% underreporting! 👉 currently 10:1 -wrong! 👉 1:1 more likely ? The Lancet Gastroenterology & Hepatology Link 🔗👇

Today, we were honored to host Jane Kraglund (regional director), Bo Libergren (chairman, regional council) and the OUH direction to talk about patient-centered research at a high international level 🎯We do it FOR and WITH our patients OUH Odense Svendborg Region Syddanmark

Exciting news about our liverscreening project!📢 DECIDE have completed the final screening of their last patient. In total since 2018= 6,500 participants in the first round of screenings and 1,450 screenings in the second round. Now it’s time to work through the data!📊

Welcome to the team Sofie!👩‍⚕️ A recent graduate now working as a research nurse in our CTU program. We look forward to her valuable contributions!🌟 #newhire #livertwitter #nurses #research

Huge congratulations to our amazing colleague, Johanne Kragh Hansen, MD, PhD, on earning her ph.d!🥳 Her research will greatly enhance our understanding of how molecules and bacteria change in steatotic liver disease. We're so proud of you, Johanne!👏 #FLASH #PhDAchievement

🍷🚫EASL will spotlight alcohol harm reduction at #EASLCongress 2025 with key events on 7–8 May, in collaboration with WHO/Europe The Opening Ceremony on 7 May will feature public health leaders from Spain, Estonia, and WHO Europe. 🌷 On the same day, the #EASLStudio session

Why do some patients remain healthy while others develop severe liver complications despite having the exact same genetic mutation in Alpha-1 Antitrypsin Deficiency?   Proud 😊- Deep Visual Proteomics at single cell level 👉in nature   nature.com/articles/s4158…   Matthias Mann Lab

🎥BTS of a Liver Scan - quick, easy and effective! Watch Maja Thiele and Katrine Tholstrup Bech demonstrate the use of our fibroscanner - a key tool we use to assess fibrosis.🔎 What is your experience with this tech? Share below!🤗👇 #livertwitter #research #healthcare #tech

On Saturday we will be joining the Festival of Science at Syddansk Universitet 🎉 💬 Why liver health matters 💥Our research projects and important findings 🎨Liver-activities for the small liver-nerds We look forward to day full of science and fun 🙏 OUH Odense Svendborg #Forsk2025 #dkforsk

🧪 New findings published in JHEP Reports benchmarking several biomarkers and combinations hereof show soluble TREM2, PRO-C3 & HOMA-IR effectively reflect changes in histological disease activity in MASLD/MASH patients in response to treatment.   doi.org/10.1016/j.jhep…

We have arrived and we are more than ready for #EASLCongress First is the opening ceremony🥳 OUH Odense Svendborg EASLnews

ALB TRIAL investigator meeting in the sun at #EASLCongress MICROB-PREDICT FLASH - Liver Research

Four successful days at #EASLCongress 2025 in Amsterdam! 💡🌷 Over 7,000 liver professionals joined — and FLASH contributed with 1 oral presentation, 3 poster tours, and 7 posters! 📢🎉 We’re returning home full of insights and inspiration. OUH Odense Svendborg EASLnews

Happy to share this RCT from GALAXY in people with ALD Out today in Nature Portfolio rdcu.be/eujFT The postbiotic ReFerm® versus standard nutritional support in advanced alcohol-related liver disease (GALA-POSTBIO): a randomized controlled phase 2 trial

To Screen—or not to screen for for advanced steatotic liver disease? Our new The Lancet Gastroenterology & Hepatology review re-examines Wilson & Jungner (1968), weighs today’s evidence, and proposes 2025 screening criteria Stine Johansen authors.elsevier.com/c/1lRV98nByrGW…